Oncolytics Biotech (ONC) to Release Earnings on Thursday

Oncolytics Biotech (TSE:ONC) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Oncolytics Biotech to post earnings of C($0.12) per share for the quarter.

Oncolytics Biotech (TSE:ONC) last posted its earnings results on Thursday, March 7th. The company reported C($0.05) earnings per share for the quarter, topping the consensus estimate of C($0.15) by C$0.10.

Oncolytics Biotech Stock Performance

Shares of Oncolytics Biotech stock opened at C$1.62 on Wednesday. The company has a quick ratio of 8.86, a current ratio of 9.01 and a debt-to-equity ratio of 1.54. Oncolytics Biotech has a 52 week low of C$1.20 and a 52 week high of C$4.49. The firm’s 50 day moving average is C$1.46 and its two-hundred day moving average is C$1.68. The firm has a market capitalization of C$122.18 million, a P/E ratio of -3.95 and a beta of 1.49.

Wall Street Analyst Weigh In

Several brokerages recently commented on ONC. Raymond James set a C$3.00 price target on shares of Oncolytics Biotech and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Cantor Fitzgerald restated an “overweight” rating on shares of Oncolytics Biotech in a research note on Friday, January 12th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.